PGGRC will approve once we are clear that the publication will not impact our commercialisation strategy;  
This needs to be cleared on two counts;
1. Is the protein used in the study 1499 able to be protected - Neil can you confirm if this is Seq id no 7041 that has been used?  if it is it is already the target in one of our patents. 
2. The method described is a process that may be useful for the manufacture of a vaccine, I have sought an opinion from our IP attorney on whether any  protection would be warranted before  release.  I will follow this up  pronto. 